The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis

Inclusion Criteria: * Male or non-pregnant, non-breast-feeding females ≥18 years old. * Participant was previously diagnosed with active mild to moderate UP/UPS and was currently experiencing symptoms of active UP/UPS disease after having completed participation in Salix's BUCF3001 (NCT01008410) or BUCF3002 (NCT01008423) study. * Willingness to undergo sigmoidoscopy. Exclusion Criteria: * Active systemic, ocular, or cutaneous infection (for example, parasitic, fungal, amoebic, viral, or bacterial disease). * History of sclerosing cholangitis, cirrhosis, or hepatic impairment, including chronic hepatitis of any etiology. * Participant took systemic, inhaled, oral, topical, or rectal corticosteroids (other than budesonide rectal foam) within 7 days of starting a treatment cycle. * Participant took ketoconazole and other potent CYP3A4 inhibitors within 7 days of starting a treatment cycle. * Participant took diuretics with cardiac glycosides. * Unstable significant cardiovascular, hepatic, renal, endocrine, neurologic, or pulmonary disease.